EMMA — Emmaus Life Sciences, Inc.

OTC · Health Care · Pharmaceuticals · CIK 822370 ·
Last close
$0.01
Market Cap
$701.9K
52W High
$0.02
52W Low
$0.01
ADV30
47,336
Next earnings
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,982,000 1,814,000 -823,000 -3,335,000 18,696,000 1,072,000 86,556,000
Dec 2025 3,852,000 3,617,000 886,000 -1,951,000 21,436,000 2,127,000 85,044,000
Sep 2025 3,378,000 3,131,000 695,000 -2,076,000 20,756,000 293,000 80,244,000
Jun 2025 2,817,000 2,667,000 -370,000 -1,135,000 23,344,000 886,000 79,045,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-11,000
Investing CF
$2,171,000
Financing CF
$-1,425,000
CapEx
$-6,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.06
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-270,067,000
Inventory
$1,555,000
Receivables
$2,804,000
ST Investments
EBIT TTM
$-349,000
Pretax Income TTM
$-7,483,000
Interest Exp TTM
$7,134,000
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 12,453,000 231,000 -7,492,000 21,436,000 85,044,000 -11,000
Dec 2024 16,653,000 -1,894,000 -6,453,000 23,602,000 80,081,000 -2,286,000
Dec 2023 29,597,000 3,540,000 -3,733,000 35,179,000 82,935,000 -1,503,000
Dec 2022 18,390,000 -6,586,000 -10,625,000 48,225,000 82,316,000 -5,073,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.07

Peers — same industry

TickerNameMarket CapLastDaily %
OWPC One World Products, Inc. $720.7K $0.01
ATXI AVENUE THERAPEUTICS, INC. $757.8K $0.23
PTIX Protagenic Therapeutics, Inc.\new $842.5K $0.47
EVFM Evofem Biosciences, Inc. $874.7K $0.01
SKVI SKINVISIBLE, INC. $924.6K $0.17

News headlines (Yahoo Finance, 1h cache)

Emmaus Life Sciences Reports Quarterly Financial Results
2026-05-15 19:51 · Yahoo
Emmaus Life Sciences Reports Annual Financial Results
2026-03-31 02:00 · Yahoo
Emmaus, NIT sign Endari distribution agreement
2025-12-31 09:57 · Yahoo
Emmaus Life Sciences Announces Strategic Transaction
2025-12-30 21:30 · Yahoo
Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
2025-06-26 13:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.